Atyr Pharma Inc. (NASDAQ:LIFE) was up 2.4% during trading on Tuesday . The company traded as high as $3.02 and last traded at $2.97, with a volume of 53,470 shares changing hands. The stock had previously closed at $2.90.

A number of equities research analysts have commented on LIFE shares. Zacks Investment Research downgraded shares of Atyr Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th. BMO Capital Markets restated a “hold” rating on shares of Atyr Pharma in a report on Thursday, May 12th. JPMorgan Chase & Co. lowered their target price on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, August 11th. Finally, Citigroup Inc. upped their target price on shares of Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday, August 16th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $6.00.

The firm’s market capitalization is $70.44 million. The firm has a 50 day moving average price of $3.08 and a 200 day moving average price of $3.62.

Atyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. On average, equities analysts forecast that Atyr Pharma Inc. will post ($2.56) earnings per share for the current year.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.